CNS Pharmaceuticals, Inc.
- CNSP
- NASDAQ
- Biotechnology
- Brain/CNS Cancer Drugs
- Oncology Biotech
$4.99
Today +2.87%Quote Oct 19, 2026, 08:00 PM UTC
−2.35%over the last month
Max drawdown −10.7%From 1-month high −8.1%3 months −7.4%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About CNS Pharmaceuticals
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily focused on developing innovative anti-cancer therapies for tumors affecting the brain and central nervous system. Its primary investigational compound, Berubicin, an anthracycline, is currently progressing through Phase I and II clinical trials as a potential treatment for glioblastoma multiforme, an aggressive form of brain cancer.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
8
Founded
2017
Market value
$7.3M
Quote Oct 19
Analyst target
$0.50
−90.0% from here
Floor
$4.97
0.5% below price
Resistance
$4.97
Price is above this level
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about CNSPPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free